Medexus Schedules Third Quarter Fiscal 2021 Conference Call

Rhea-AI Summary

Medexus Pharmaceuticals plans to host a conference call at 8:00 AM ET on March 2, 2021, to discuss its financial results for the third quarter of fiscal 2021, which ended on December 31, 2020. The company will file its financial statements on March 1, 2021. Investors can access the call via phone or through a webcast. Medexus focuses on orphan and rare diseases, providing products like Rasuvo™ and IXINITY® for conditions including rheumatoid arthritis and Hemophilia B. For further insights, the company promotes its commitment to quality, innovation, and customer service.

Positive

• Plans to discuss Q3 financial results, indicating transparency and stakeholder engagement.
• Focus on orphan and rare diseases positions Medexus in a high-demand market.
• Strong commercial platform and commitment to innovative healthcare products.

Negative

• None.

TORONTO and CHICAGO and MONTREAL, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021 to discuss the Company’s financial results for the fiscal 2021 third quarter ended December 31, 2020, as well as the Company’s corporate progress and other developments. The Company expects to file its financial statements along with its MD&A post market on March 1, 2021.

The conference call will be available via telephone by dialing toll free 888-506-0062 for Canadian and U.S. callers or +1 973-528-0011 for international callers and using entry code 414918. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2010/40181 or on the Company’s Investor Events section of the website: https://www.medexus.com/en_US/investors/news-events.

A webcast replay will be available on the Company’s Investor Events section of the website (https://www.medexus.com/en_US/investors/news-events) through Wednesday, June 2, 2021. A telephone replay of the call will be available approximately one hour following the call, through Tuesday, March 9, 2021 and can be accessed by dialing 877-481-4010 for Canadian and U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 40181.

About Medexus Pharmaceuticals Inc.

Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.

For more information, please contact:

Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: ken.dentremont@medexus.com

Roland Boivin, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 514-344-8765
E-mail: roland.boivin@medexus.com

Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
Email: mdp@crescendo-ir.com

Investor Relations (Canada):
Tina Byers
Adelaide Capital
Tel: 905-330-3275
E-mail: tina@adcap.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FAQ

When will Medexus Pharmaceuticals announce its Q3 financial results?

Medexus Pharmaceuticals plans to file its Q3 financial results on March 1, 2021.

What time is the Medexus Pharmaceuticals conference call scheduled?

The conference call is scheduled for 8:00 AM Eastern Time on March 2, 2021.

How can I access the Medexus Pharmaceuticals conference call?

The call can be accessed via telephone at 888-506-0062 for Canadian and U.S. callers or +1 973-528-0011 for international callers, using entry code 414918.

What are the main products of Medexus Pharmaceuticals?

Medexus Pharmaceuticals focuses on products like Rasuvo™, IXINITY®, and Rupall® for auto-immune diseases, Hemophilia B, and allergy treatment.

What is Medexus Pharmaceuticals' focus area?

Medexus Pharmaceuticals is focused on orphan and rare diseases, along with therapeutic areas like auto-immune disease, hematology, and allergy.